In a report released today, Steven Lichtman from Oppenheimer assigned a Buy rating to Integra Lifesciences (NASDAQ: IART), with a price target of $74. The company’s shares closed yesterday at $64.54, close to its 52-week high of $65.32.
Lichtman commented:
“During our recent time on the road with IART, management highlighted confidence in its long-term sales target of 5-7% organic growth and ~10% including tuck-in acquisitions. R&D productivity is accelerating as evidenced by an increase in the number of new product launches expected in ’18 (16 versus 4-5 the past couple of years). While the pipeline is balanced across segments, IART’s r egenerative portfolio represents the highest growth and margin opportunity. International should also be an increasing tailwind as product registrations accelerate and IART benefits from a significantly larger footprint post the Codman acquisition. And balance sheet flexibility is increasing during ’18, with more tuck-in deals likely in the medium term. Near term, our sense is that the commercial changes/Codman integration remain on track.”
According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.3% and a 53.7% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Wright Medical Group, K2M Group Holdings, and Tandem Diabetes.
Integra Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $64.
See today’s analyst top recommended stocks >>
The company has a one-year high of $65.32 and a one-year low of $41.51. Currently, Integra Lifesciences has an average volume of 609.2K.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2018, Richard Caruso, a Major Shareholder at IART sold 32,880 shares for a total of $1,764,998.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
